drugset / Trial / NCT00083525
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
Timeline
- Start
- 2004-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WX-UK1 | Unknown | — | — |
| Background | Capecitabine | Small molecule | — | — |